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Research in Translation
Cutaneous malignant melanoma (MM) falls into two main groups, based on aetiology 
[1–3]. First, a small minority of patients 
have acral MM, in which the disease 
occurs on the palms and soles. The 
incidence of acral MM is similar in 
people with widely different skin 
colours (and hence with different 
amounts of skin melanin), and at 
different latitudes. The palms and 
soles have a thick epidermis, and so 
few harmful photons of ultraviolet 
radiation (UVR) will penetrate to the 
germinative layers. Acral melanomas 
are therefore not believed to be 
causally related to UVR, and their 
aetiology remains a mystery. They will 
not be discussed further in this article.
By contrast, more than 90% of 
MM occurs on non-acral sites and is 
thought to be caused by UVR [2,4]. The 
evidence for such causality comes from 
a variety of ﬁelds. MM is most common 
in those with pale skin, which has a 
relative lack of melanin, a substance that 
blocks photons from penetrating deeply 
into skin [2]. African people with 
very dark skin are hundreds of times 
less sensitive to the harmful effects of 
UVR than white Northern Europeans. 
Even within white Northern European 
populations, MM rates vary in relation 
to more subtle degrees of difference 
in sun sensitivity. Those with red hair, 
pale skin, and a tendency to freckle are 
about three times more likely to develop 
MM than those without these three 
features [2,5]. The dramatically elevated 
rate of MM in those with European 
ancestry in Australia is therefore 
what we would expect: susceptibility 
of the host coupled with enhanced 
environmental exposure leads to a high 
disease risk [4]. 
However, it is not just epidemiology 
that implicates a key role for UVR. 
Patients with the rare Mendelian 
disorder xeroderma pigmentosa (see 
http://www.ncbi.nlm.nih.gov/entrez/
dispomim.cgi?id=278700) have a 
dramatically increased risk of most 
types of skin cancer, including MM. 
This disorder is characterised acutely by 
sun-burn in response to tiny amounts 
of UVR, and both this sun-burn and 
the elevated cancer rates are a result 
of an inability to repair the DNA 
damage induced by UVR. The lesson 
is quite clear: it is not sunlight per se, 
but the highly mutagenic UVR part of 
the electromagnetic spectrum that is 
important for skin carcinogenesis.
Given that we know the major host 
and environmental factors that lead 
to non-acral melanomas, one might 
think that we know enough to reduce 
the incidence of MM. But our ability to 
change people’s behaviour so that they 
reduce their exposure to UVR remains 
limited. In addition, as our knowledge of 
MM has increased, so has the incidence 
of disease. Puzzling gaps therefore 
remain in our knowledge of the 
aetiology of non-acral melanomas. So 
what important things do we not know?
Gaps in Our Knowledge of the 
Aetiology
First, although MM is related to UVR 
exposure, the body site distribution of 
MM does not match the distribution of 
some other sun-related cancers, such 
as squamous cell carcinoma (SCC) of 
the skin [6,7]. SCC is most common on 
the backs of the hands, the face, and 
the scalps of bald men: these are the 
sites that receive the highest cumulative 
dose of UVR. By contrast, when the 
body site distribution of MM is mapped 
out, we see that sites such as the 
shoulders and back in men, and lower 
legs in women, show relatively higher 
rates of MM. I say relatively because 
obviously the different body sites differ 
in surface area, but the point is that 
we see a difference between SCC and 
melanoma on the basis of the same 
human anatomy. If the amount of UVR 
received is to explain MM aetiology, 
then we need to factor in some other 
modifying hypothesis. Perhaps the 
pattern of exposure is important, with 
sites that are intermittently exposed 
behaving differently from those that 
are continually exposed. It is this line 
of argument that contributed to the 
hypothesis that acute episodes of “sun-
burning” (rather than cumulative dose 
of UVR) may be important [3,6,8]. 
Second, SCC rates increase 
exponentially with age, as do most 
human cancers. Melanoma is again 
different, with a curious interaction 
between age and site [7]. MM on sun-
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Linked Research Article
This Research in Translation discusses 
the following new study published in 
PLoS Medicine:
Viros A, Fridlyand J, Bauer J, 
Lasithiotakis K, Garbe C, et al. (2008) 
Improving melanoma classification by 
integrating genetic and morphologic 
features. PLoS Med 5(6): e120. 
doi:10.1371/journal.pmed.0050120
Boris Bastian and colleagues present 
a refined morphological classification 
of primary melanomas that can be 
used to improve existing melanoma 
classifications by defining genetically 
homogeneous subgroups.
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exposed sites such as the face increases 
with age, as does SCC, but on other 
body sites the incidence peaks far 
earlier in adult life [2]. Perhaps there 
are different mechanisms operating 
at different sites? What we do know is 
that whatever aetiological differences 
there are, the prognosis of the resulting 
tumours (using standard indicators) is 
similar at the different sites.
Third, the incidence of melanoma 
has increased steadily in most 
European-derived populations over 
the last 40 years or more. Rates vary by 
country, but annual increases of 3%–
7% are the norm [2]. Conventional 
wisdom is that increased exposure 
to the sun in the form of changes in 
behaviour (essentially increases in, 
and changed patterns of, leisure) 
underpin these rates [9]. The case is 
persuasive, but we still lack objective 
measures of personal sun exposure 
over the lifetime of individuals. Studies 
using UVR-sensitive badge monitoring 
of individuals do show that whatever 
the ambient UVR, personal behaviour 
is a key factor in determining sun 
exposure: many children in Northern 
England will receive more UVR than 
children in Queensland, Australia [10].
But there is another aspect of 
the increase in diagnosed cases 
that is perhaps more critical still, a 
phenomenon that is seen in many 
other tumour types that receive more 
medical attention: we may be picking 
up “earlier” lesions, but at the cost of 
not knowing the biological behaviour 
of the lesions we detect. The question 
can be usefully framed as follows: 
to what extent does melanoma 
histopathology reﬂect biological 
behaviour? To understand this issue, 
we need to look more closely at what 
happens in the clinic rather than just in 
the research laboratory.
The Clinical Picture
In the early part of the 20th century, 
the clinical picture of melanoma was 
of a highly malignant tumour that 
presented late and carried a high 
mortality at ﬁve years of about 80% [1]. 
Then, as is still largely the case today, 
there was no curative treatment for 
metastatic disease. Judged in terms of 
absolute tumour mass MM appears to 
metastasise early and, in the absence 
of insights into how to treat metastatic 
disease, the mantra has been to 
detect melanoma early before it has 
metastasised. Although we have no 
evidence for the value of population 
screening for MM, over the last century 
greater access to health care and 
increasing knowledge and concern 
about MM led to patients presenting 
earlier with lesions that might be MM 
[3]. Rather than a ﬁve-year death rate 
of 80% or greater, we now see a survival 
rate at ﬁve years of 80% or more [2]. 
It would seem natural to attribute the 
increased survival of patients with MM 
to the increased detection of early 
disease. 
The most useful prognostic 
predictor for MM is the Breslow 
thickness [11], essentially a measure 
in millimetres of the vertical depth 
of the lesion measured on a routine 
histopathology slide. A number 
of different morphological terms 
(e.g., nodular melanoma, superﬁcial 
spreading melanoma) have been used 
to classify melanoma, but they add little 
if anything to the information provided 
by the Breslow thickness (although they 
my reﬂect aetiological differences). 
Over time, the mean Breslow thickness 
has declined in many populations, 
a testament to earlier and earlier 
detection of MM.
The “Non-Metastasising 
Hypothesis”
The combination of increasing 
incidence of a disease with a reduction 
in case fatality has led to  other 
hypotheses [9]. In the 1990s, based on 
examination of epidemiological trends 
in Australia, Burton and Armstrong 
[12] argued that dramatic increases in 
thin melanomas (in terms of Breslow 
thickness) and no reduction in the 
number of thick MMs suggested that 
many lesions being detected were 
(in their words) “non-metastasising 
MM”. The argument was that on top 
of the real increases in MM capable 
of metastases, increased sampling led 
to lesions that were biologically more 
benign being histopathologically 
classed as MM—a scenario familiar to 
students of other human cancers such 
as breast and prostate. This scenario 
is also seen in the skin with non-
melanoma cancers: actinic keratoses, 
lesions with multiple genetic changes 
that were once thought to be the 
hallmark of cancer, regress without any 
treatment in most cases [13]. The more 
you look for squamous cell carcinomas, 
the more actinic keratoses you biopsy.
However, the “non-metastasising 
MM” hypothesis [12] is frustratingly 
difﬁcult to prove in the real world 
where we study patients rather than 
laboratory mice. If a clinician ﬁnds 
a skin lesion that looks remotely 
suspicious of a melanoma, it must be 
excised—usually a simple, almost trivial 
procedure. But once the lesion is ﬁxed 
in formalin, all we have as our guide 
is the pathologist’s interpretation of 
morphology—not the natural history 
of the lesion, the standard test of 
biological behaviour. How can we infer 
Five Key Papers in the Field
Yee EFT, Hoffman RM, Berwick M 
(2007) Early diagnosis of melanoma: 
What do we know? Gital Dermatol 
Venereol 142: 55-70 [3].  
An authoritative and lucid review 
that critically examines most aspects 
of melanoma epidemiology, with an 
emphasis on the diagnosis of early 
lesions.
Landi MT, Bauer J, Pfeiffer RM, Elder 
DE, Hulley B, et al. (2006) MC1R 
germline variants confer risk for BRAF-
mutant melanoma. Science 313: 521-
522. 
An intriguing paper, building on previous 
work by others suggesting that the 
aetiological pathways for melanomas 
at different body sites may be different, 
which proposes links between two 
hitherto unrelated molecular pathways.
Welch HG, Woloshin S, Schwartz LM 
(2005) Skin biopsy rates and incidence 
of melanoma: Population based 
ecological study. BMJ 331: 481. 
A provocative paper that suggests that 
over-diagnosis based on increasing 
biopsy rates may account for some of the 
putative increases in reported melanoma 
rates
Edman RL, Klaus SN (2000) Is routine 
screening for melanoma a benign 
practice? JAMA 284: 883-886. 
A welcome attempt to counter the 
widespread assumption that population 
screening for melanoma has no down-
sides.
Burton RC, Coates MS, Hersey P, 
Roberts G, Chetty MP, et al. (1993) An 
analysis of a melanoma epidemic. Int.J 
Cancer 55: 765. 
Based on analysis of epidemiological 
trends in Australia, this was the first paper 
to argue that there may exist a subset of 
melanomas that do not metastasise. 
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natural history when the sample has 
been removed? 
There would seem to be two 
possible solutions to this conundrum, 
one old and one new. First, if some 
histopathological changes that are 
considered typical of MM are found 
more widely, say in patients who die for 
other reasons, then it may be possible to 
estimate their prevalence and use these 
base rates to inform the signiﬁcance of 
such changes in a clinical context of a 
suspicious lesion. We already know that 
the histopathological interpretation 
of melanocytic lesions is difﬁcult, 
and that there is signiﬁcant variation 
in reporting between even specialist 
melanoma pathologists [3,14], so any 
design must allow for such factors. 
Today it might be far harder to gain 
regulatory approval for such a study 
than it would have been a generation 
ago.
The second approach is to hope 
that technology and the vogue for 
large patient cohorts (as part of large 
collaborative studies) may help us. A 
study in this issue of PLoS Medicine, 
of a cohort of 302 archival tissues 
of primary cutaneous melanomas, 
provides such an example [15]. Boris 
Bastian and colleagues examined 
a range of (histopathological) 
morphological criteria and related 
these changes to mutations in BRAF 
and NRAS, two genes previously 
known to be important in melanoma 
pathogenesis. The authors then 
showed, in an independent cohort, that 
these morphological changes could 
be used as a proxy for genetic analyses 
and clinical outcome predictions. The 
emphasis on morphology gleaned 
from routine histopathological samples 
is important: it remains salutary that 
examination of melanocytic lesions 
using microscopic morphology remains 
more informative than any products of 
the genomics revolution—or any other 
“-omics” for that matter. 
The ability to mine data from 
retrospective collections, where long-
term survival information is available, 
is therefore very important. But the 
potential utility of such collections 
may also change. Just as the Breslow 
thickness [11] allows us to distinguish 
groups of patients with very thin lesions 
who have an uncertain prognosis from 
patients without melanoma [2], new 
technologies—if they can be applied 
to the small ﬁxed biopsy samples of 
melanoma—might allow us to gradually 
detect more and more markers that 
predict outcome. Gradually, if one is an 
optimist at least, we may bootstrap our 
knowledge of those lesions that “look 
like MM” but show clinical outcomes 
that are indistinguishable from those of 
age-matched controls. There may be no 
Eureka moment, rather just a gradual 
tightening of conﬁdence limits on what 
we may say. 
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